This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite a slew of prescription options and widespread advertising pushes, most patients are sticking with over-the-counter (OTC) remedies rather than trying new preventive medications, according to Phreesia Life Sciences’ survey results collected from more than 4,000 patients checking in for their doctors’ appointments in July 2021.
Can more than 20 pharma companies unite around messaging for biomarker testing even though everyone seems to call it something different? Historically, pharma companies only do marketing for biomarker testing related to the type of drug they were launching,” says Nikki Martin, Senior Director, Precision Medicine Initiatives, LUNGevity. “As
It was marketed aggressively to doctors and was touted as a safer alternative to other pain relievers on the market. However, it was later discovered that the drug increased the risk of heart attacks and strokes, and it was eventually pulled from the market in 2004. Another example is the case of Purdue Pharma and the opioid crisis.
It's become the main thing that the doctors are looking at now. When he was going through his cancer, he died in 2004. It broke the confines of you being a doctor learning healthcare, learning to be a medical profession and that stayed there; it just broke it all. Interview Transcription (mild edits). And that's how it started.
One likened the firm’s earnings from advising Purdue Pharma and other pharmaceutical companies to “blood money” from drug traffickers. Yet, pharma continues to be aligned with MBA spreadsheet consulting. I couldn’t believe what I heard during a McKinsey report on a pharma company’s oncology drug.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content